The document discusses Cancer Genetics' focus on personalized cancer treatment through genomics. It provides an overview of Cancer Genetics' business model, which utilizes molecular diagnostic testing to support the cancer care continuum and improve outcomes. Key acquisitions are highlighted that expand Cancer Genetics' capabilities in clinical services, research, and pharmacogenomics.
Global cancer vaccines market & pipeline analysisKuicK Research
“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:
Global Cancer Market Overview
Personalized Cancer Vaccines: Progress & Possibilities
Platforms for Cancer Vaccines Delivery
Cancer Vaccines: Mechanism & Innovations
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
Marketed Cancer Vaccines: 12 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
Cellgen Diagnostics is an early stage venture that is developing a break through Companion Diagnostic platform that will enable Precision Medicine by determining whether a patients genetic profile is a match for the prescribed cancer therapeutic.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences
Exact Sciences CEO Kevin Conroy delivers an update on the commercial launch of Cologuard and tells the Exact Sciences story at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco California. The presentation took place January 14, 2015.
Global cancer cdk inhibitors market & clinical pipeline outlook 2022KuicK Research
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report highlights:
* Selectivity and Working Mechanism of a Cancer CDKs Inhibitor
* Recent Advances in the CDKs Related Cancer Therapy
* Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline
* Market Opportunity Assessment: More Than US$ 20 Billion (2022)
* Price Analysis of Cancer CDKs Inhibitors:
* Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Andrew Aijian
Analysis and synthesis of a pulse survey conducted across >140 oncologists, pathologists, and lab directors regarding current adoption and trends associated with emerging oncology biomarkers and companion diagnostics (CDx), with an emphasis on next-generation sequencing (NGS)-based CDx.
Global cancer vaccine market & pipeline analysisKuicK Research
“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:
Global Cancer Market Overview
Personalized Cancer Vaccines: Progress & Possibilities
Platforms for Cancer Vaccines Delivery
Cancer Vaccines: Mechanism & Innovations
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
Marketed Cancer Vaccines: 12 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Global cancer vaccines market & pipeline analysisKuicK Research
“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:
Global Cancer Market Overview
Personalized Cancer Vaccines: Progress & Possibilities
Platforms for Cancer Vaccines Delivery
Cancer Vaccines: Mechanism & Innovations
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
Marketed Cancer Vaccines: 12 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
Cellgen Diagnostics is an early stage venture that is developing a break through Companion Diagnostic platform that will enable Precision Medicine by determining whether a patients genetic profile is a match for the prescribed cancer therapeutic.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences
Exact Sciences CEO Kevin Conroy delivers an update on the commercial launch of Cologuard and tells the Exact Sciences story at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco California. The presentation took place January 14, 2015.
Global cancer cdk inhibitors market & clinical pipeline outlook 2022KuicK Research
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report highlights:
* Selectivity and Working Mechanism of a Cancer CDKs Inhibitor
* Recent Advances in the CDKs Related Cancer Therapy
* Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline
* Market Opportunity Assessment: More Than US$ 20 Billion (2022)
* Price Analysis of Cancer CDKs Inhibitors:
* Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Andrew Aijian
Analysis and synthesis of a pulse survey conducted across >140 oncologists, pathologists, and lab directors regarding current adoption and trends associated with emerging oncology biomarkers and companion diagnostics (CDx), with an emphasis on next-generation sequencing (NGS)-based CDx.
Global cancer vaccine market & pipeline analysisKuicK Research
“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:
Global Cancer Market Overview
Personalized Cancer Vaccines: Progress & Possibilities
Platforms for Cancer Vaccines Delivery
Cancer Vaccines: Mechanism & Innovations
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
Marketed Cancer Vaccines: 12 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
The Science of Launching and Achieving Growth in Oncologyaccenture
We have conducted research to understand how oncology companies are responding to New science, more treatment choices and changing economics. Visit https://accntu.re/2Jn72wq to learn our key takeaways for launching and achieving growth in oncology.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
Corporate Presentation TiGenix - September 2014TiGenix
This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company.
This document may contain forward-looking statements and estimates made by the Company, including with respect to the anticipated future performance of TiGenix and the market in which it operates. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this document and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Strand featured in CIO Review: Pharma and Life Science Special edition - July 2014
Strand Genomics Inc recognised by CIO Review as one among 20 most promising Tech solution providers to Pharma and Life science industry 2014
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Dócola is a social good organization with the only free care communication platform that consolidates thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Plus, you can easily create and upload your own resources.
INNO HOLDINGS INC. is an innovative building-technology company with a mission to transform the construction industry with our proprietary cold-formed steel- framing technology and other building innovations
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
2. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 2
Forward-Looking Statement
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services or Gentris, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks related to integration of the acquisitions of Gentris and BioServe and the realization of the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended June 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
3. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 3
Focused On Personalizing Cancer Diagnosis and Treatment
Globally Through Genomics
Develop & Commercialize Unique Targeted Panels For The
Comprehensive Assessment of Cancer
Develop Compelling Collaborations With Leading Institutions To Support
Genomic Test Adoption, Validation & Health Economics
Establish Sales, Marketing & Commercial Infrastructure In US & India
Serve Both the Clinical and Biopharma Communities Leveraging A
Standardized Global Infrastructure
Selectively Acquire Companies & Capabilities That Further Our Mission of
Impacting The Personalization of Cancer Diagnosis & Management
4. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 4
Molecular Diagnostics are Changing our Understanding of Cancer While Providing New Tools to Diagnose & Treat Patients
Our unique focus & approach supports the entire cancer care continuum
Personalize therapeutic plan and treatment options
DIAGNOSIS
PROGNOSIS
THERANOSIS
Assist in patient outcome and disease management
What drug(s) to give, how much, and when?
What are my survival prospects?
Do I have cancer and what type?
Use genomics to provide an accurate and definitive typing of the cancer
Proprietary Products Focused Oncology Lab Comprehensive Report
Integrated Molecular Diagnostic Testing Brings Benefits
Across the Entire Oncology Ecosystem
5. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 5
CGI’s Mission is to Personalize and Improve the Success Rate in Cancer Treatment
Integrating & Delivering Genomic Information About a Patient’s Cancer
Can Improve Care & Reduce Cost
Phenotypic & Physical Examination
Morphologic & Pathological Analysis
Large & Multiple Specimens Required
Significant Delays to Treatment
Traditional Approach
Biomarkers and Companion Diagnostics
Genomic Analysis & Proprietary Algorithms
Reduced Size and Number of Specimens
Improved Diagnoses & Treatment Plans
Our Approach: Personalized Medicine
Target For Tomorrow
25%
Situation Today
Source: Clinical Trends in Molecular Medicine, Vol. 7, Issue 5
100%
Success Rate
Target Success Rate
6. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 6
The Acquisitions of BioServe India and Gentris Corporation Provide Significant Market Upside & Improve CGI’s Competitive Position
•Growth potential in integrating our oncology- focused testing capabilities with Gentris’ high-value contracts.
•Expansion of Gentris’ capabilities and portfolio to include oncology-focused pharmacogenomics services.
•24,000 sq. foot lab space (CLIA/CAP/GLP) with NGS, genotyping, and gene expression test capabilities.
Gentris Corporation
[Closed 7/16/14]
•Access to high-growth Indian diagnostics market – projected to grow at 15-20% per annum for the next decade.
•Accelerates next-generation sequencing development and validation of targeted hot spot oncology panels.
•Cost-effective expansion of genomic analysis & informatics capabilities with state of-the-art 14,000 sq. foot lab.
BioServe India
[Closed 8/18/14]
7. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 7
Our Expansion is Crucial for our Global Positioning as an Industry Leader in Genomics Testing and Services
Clinical Services and R&D
82 Employees as of July 1st
CGI is positioned as leader in oncology-focused genomics and is enabled to deliver
complete solutions to the clinical and research communities.
Clinical & Research Services
Addition of 33 employees
Pharmacogenomics Services
Addition of 41 employees
8. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 8
Unique, Scalable and Multifaceted Business Model With A Focus On Providing A Complete Solution
Suite of Products and Services Provides Multiple Growth Drivers and Value to Multiple Parties: Clinical Community, Biopharma & Medtech
CLINICAL SERVICES
Differentiated and complete disease-focused solutions
Superior turnaround times
World-class expertise in genomics and cytogenetics
Serving community hospitals and labs through unique Expand Dx™ program
BIOPHARMA PARTNERSHIPS
Biomarker and companion diagnostic development
World-class genomics and bioinformatics
Drug-specific and cancer-specific assays
Comprehensive focus in hematologic & urogenital cancers
PROPRIETARY PRODUCTS
Proprietary molecular diagnostics & FISH probes
Clinically validated
IP-protected
Sold globally
Probe manufacturing leverages low-cost, high scale facility in India
9. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 9
Our Target Markets in Oncology Testing Comprise Over 615,000 New Lives Annually in the U.S.
Ability to Impact Over 615,000 New Lives Annually in the U.S.
Source: American Cancer Society
156,420
2014 Estimated New Cases
(U.S.)
Death Rate 35%
Hematological:
Lymphoma, Leukemia, M. Myeloma
371,610 2014 Estimated New Cases (U.S.)
Death Rate 16%
Urogenital:
Kidney, Bladder & Prostate
86,970
2014 Estimated New Cases
(U.S.)
Death Rate 31%
Gynecological:
Cervical, Endometrial & Ovarian
6 Products Launched in Target Segments Over $6Bn in Annual U.S. Spend on Lab Testing In These Categories
10. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 10
6 Proprietary Diagnostic Products Commercially Launched & In Market
Incidence
Indication
Hematologic Cancers
106,770
(Annual New Cases, Global)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
142,360
(Annual New Cases, Global)
Diffuse Large B-Cell Lymphoma
62,300
(Annual New Cases, Global)
Follicular Lymphoma
17,795
(Annual New Cases, Global)
Mantle Cell Lymphoma
Urogenital Cancers
274,000
(Annual New Cases, Global)
Kidney Cancer
HPV-Associated Cancers
(FHACT®)
1,750,000
(Annual New Cases, US)
HPV+ Low Grade Cervical Lesions
Over 2.3 Mn Combined Annual New Cases Globally
11. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 11
Product Pipeline
Research &
Discovery
Clinical
Development
Commercial Development
Launch &
Market Entry
Indication
Development Stage
Hematologic Cancers
Multiple Myeloma
Comprehensive Myeloid Panel
[NGS-based]
Comprehensive CLL Panel
[NGS-based]
UroGenital Cancers
Bladder Cancer
Comprehensive Renal Panel
[NGS-based]
Cervical Cancer
HPV-Associated Cancers
(FHACT®)
Head & Neck Cancer
12. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 12
Despite Improved Cancer Care, Case Numbers for Hematologic Cancers are Still Rising
Genomics-Based Tests like MatBA® are Critical and Improve the Management and Cost of Hematologic Cancers
Source: Genzyme & Nature
Source: National Cancer Institute, National Center for Health Statistics, SEER Dataset of Incidence & Mortality, FDA
1
2
5
12
89
100
80
60
30
2
Number of Years Ago
11.1
12.6
15.5
18.5
20.0
19.7
20.5
21.2
5.6
6.2
7.1
7.9
8.7
8.2
6.9
7.3
1975
1980
1985
1990
1995
2000
2005
2010
Incidence Rate
Survival Rate
Identified Leukemia & Lymphoma Subtypes
Incidence & Survival Rates for NHLs
(US Only, per 100,000)
13. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 13
MatBA®-CLL/SLL Improves Risk Stratification & Outcome Prediction
Validated in Collaboration w/ Dr. Kanti Rai & Dr. Nicholas Chiorazzi (NSLIJ); 2 Datasets, 322 specimens
Additional Validations being conducted w/ HUMC & Dana Farber; 2 Cohorts, 350+ specimens
█ Favorable
█ Intermediate
█ Unfavorable
█ Favorable/
Intermediate
(no distinction)
38% of cases in our study have a favorable prognosis falling under "watch & wait" approach.
8% of cases with unfavorable prognosis missed by FISH and caught using MatBA®-CLL/SLL.
Impact on therapy selection & clinical management of CLL patients.
Genomic Aberrations Reported
by FISH:
4
Genomic Aberrations Reported
by MatBA®-CLL/SLL:
20
85%
15%
FISH
23%
39%
38%
(Current Method)
(CGI Method)
14. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 14
MatBA® can Group Patients into Risk Groups & Prognostication Classes
MatBA®- CLL / SLL is a diagnostic tool and prognostic indicator for patient stratification and improved patient management
Being actively used in clinical care, in clinical trials and in validation programs with Dana Farber, MSKCC and HUMC
20 key genetic events/sites classify CLL patients as having the potential for Poor outcome = High risk Intermediate outcome = Intermediate risk Good outcome = Low risk Detection of specific genomic imbalance in CLL/SLL by MatBA®-CLL/SLL correlates patient risk with time to first treatment (TTFT) and shorter overall survival (OS)
Patients classified as high risk showed a shorter TTFT compared to those classified as low or intermediate risk
Patients classified as high risk had significantly shorter OS times than those classified as low or intermediate risk
Provides additional risk stratification between low and intermediate risk patients, not currently available in other tests
Time to First Treatment (TTFT)
Time (months)
Time (months)
Proportion Surviving
Proportion Treatment- Free
– GOOD (n=74)
– INTERMED (n=107)
– POOR (n=47)
– GOOD (n=74)
– INTERMED (n=107)
– POOR (n=47)
P = 0.090
P = 0.001
P < 0.001
P = 0.010
Overall Survival (OS)
Leukemia & Lymphoma – Houldsworth, et. al Sept. 18, 2013
15. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 15
UroGenRA®-Kidney Can Guide Management of Patients with Renal Masses and Appropriate Treatment Selection
Clinical Benefits Include Reduction in Number of Highly Invasive Procedures and Time to Treatment Initiation, and Better Informed Treatment Selection
Development of diagnostic algorithm
>600 RCC malignant subtypes (in-silico: SNP)
>100 malignant and benign renal neoplasms (in-house: aCGH & FISH) Retrospective in-house FFPE validation (n>190) CCF
100% diagnostic yield
97% diagnostic sensitivity to distinguish benign from malignant renal neoplasms
93% sensitivity to distinguish malignant RCC subtypes
C. Magi-Galluzzi and E. Klein (Cleveland Clinic) Prospective ongoing percutaneous core needle biopsy (n>50) MSKCC
Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to surgical intervention
J. Coleman and J. Durack (MSKCC)
PROBLEM
Men and women with renal masses often undergo unnecessary nephrectomy for accurate diagnosis and experience delay in treatment
SOLUTION
UroGenRA® will detect genomic aberrations in a single assay permitting accurate diagnosis (benign vs malignant, and malignant subtype) guiding appropriate management and treatment strategies
16. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 16
FHACT® - A New Genomic Aid In The Screening & Management Of Cervical Cancer
FHACT® Provides Critical Information Which Reduces
Unnecessary and Costly Colposcopies
Cervical cancer effects nearly 500,000 women globally each year with nearly 80% in developing countries.
Today, all these women are referred for colposcopy.
Women with abnormal or unclear Pap smears
55 Million
Pap smears per year
3.5 Million
Pap smears come back as unclear/abnormal
2 Million
biopsies performed
12,000
cases of cervical cancer
17. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 17
FHACT® Provides Information for Developing Treatment Plans Potentially Reducing Healthcare Costs & Procedures
FHACT® is the Only 4 Color FISH Probe that can be Used for Cervical Cancer Screening
as Additional Testing Before Referral for Colposcopy
Global Validation Partners
Genomic Amplification by Disease Category
Source: P. Luhn, J. Houldsworth, et al., Gynecologic Oncology (2013)
5
10
19
20
0
20
40
60
80
ptrend = 0.01
6
9
9
20
0
20
40
60
80
ptrend = 0.02
6
9
7
12
0
20
40
60
80
ptrend = 0.03
3
8
12
12
0
20
40
60
ptrend = 0.001
<CIN2
& NLIM
(n=11)
<CIN2 & LSIL (n=20)
CIN2
&/or HSIL
(n=10)
CIN3+
(n=7)
<CIN2
& NLIM
(n=11)
<CIN2
& LSIL
(n=20)
CIN2
&/or HSIL
(n=10)
CIN3+
(n=7)
FHACT® detects irreversible changes in cervical cells caused by HPV.
18. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 18
IP Position and Detailed Global Strategy
Strong and growing portfolio in molecular-focused patents for disease identification and stratification
IP-based on unique algorithms across a broad group of chromosomal regions
Validation of specific clinical endpoints that are associated with particular disease outcomes or decisions
Filing and maintenance of trademark portfolio
Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms
US Issued Patent 8,580,713
US Issued Patent 8,557,747
Europe 10803548.6
India 6657/DELNP/2012
Canada 2,785,656
Methods of Analyzing Chromosomal Translocations Using Fluorescence In Situ Hybridization (FISH)
US Issued Patent 7,585,964
US Issued Patent 7,964,345
Canada 2,447,320
Panel for the Detection and Differentiation of Renal Cortical Neoplasms
US Issued Patent 8,603,948
US 14/078,726
Europe 08844570.5
Methods for Detecting Human Papilloma Virus-Associated Cancers
US 13/227,027
US 13/474,111
PCT/US2011/050681
Methods and Tools for the Diagnosis of Female Gynecological Cancers and Precancers
US 61/581,350
19. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 19
Large, Targeted Market Opportunities
Target Markets
Commercialization Strategy
Community Hospitals
Regional Cancer Centers
Oncologists and Pathologists
Continue to growing sales force that calls on hospitals and regional laboratories
Plan development of national footprint through Expand Dx™
Biotechnology Companies
Pharmaceutical Companies
Leverage clinical infrastructure and proprietary product portfolio for testing services that support clinical trials
Expand sales emphasis of Select One®
Emerging Markets
Enhance distributor base in select emerging economies
Partner with leading local cancer care providers and hospitals to provide probes, arrays and clinical services
Collaborate to create and validate microarrays and other proprietary products
Accelerate launch of large scale studies
Universities and Research Centers
20. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 20
Unique Service Offering Developed to Enable Community Hospitals to Improve Cancer Outcomes & Treat Patients Locally
Delivers better outcomes to community hospitals and laboratories
Enables community hospitals to bring “state-of-the-art” genomic testing to patients
Brings personalized medicine to the community hospital vs. just at academic and teaching hospitals
Allows community hospitals to keep patients and treat them locally
Improving care and quality is critical to maintaining reimbursement for community hospitals
$600,000 - $800,000 USD in Testing Opportunity on Average per Hospital
Expanding & Developing Cancer Care is a Top Priority for Hospital CEOs & CFOs
4,000 to 5,000 Community Hospitals & Laboratories in the U.S.
85% Of All U.S. Cancer Patients are Initially Diagnosed in Community Hospitals & Laboratories
21. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 21
Through Acquisition, Clinical Trial Services Show Strong Growth and Robust Pipeline
Gentris Provides Pharmacogenomic Clinical Trial Services to Several Large Pharma Companies Including Merck, Novartis, Otsuka, Eisai and Bristol-Myers Squibb
GROWTH IN CGI’s SELECT ONE® CONTRACTS ($000)
21%
55%
ONCOLOGY DRUGS ASSOCIATED WITH BIOMARKER(S)
$300
$2,700
$8,500
$18,000
2011
2012
2013
2014
Approximate value of contracts with biotech and pharma clients
2011
2016
Source: Company Analysis and Management Estimates
22. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 22
Over 6,800 Oncology Trials in the US Aligned with our Core Markets
Number of Open Clinical Trials (U.S.)
1,439
1,453
2,178
1,765
Lymphoma
Leukemia
Urogenital
HPV-Associated
Source: www.clinicaltrials.gov
23. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 23
Gilead is Currently Using a Comprehensive Panel of CGI Services & Proprietary Products in National & International Trials for Hematologic Cancers
The Gilead Relationship Exemplifies the Significant Upside Potential of
CGI’s Select One® Offering
Highlights
Comprehensive, biomarker-based patient profiling will help risk stratification and response monitoring
Improved patient profiling will result in improved trial efficacy for Gilead
Testing will occur across several methodologies, including flow cytometry, FISH, sequencing and mutation assays, and MatBA® microarrays
CGI provides biomarker driven insight regarding patient targeting and potential outcomes
Trials cover both national and international locations with all patient specimens being processed in Rutherford, New Jersey
CGIX Press Release: Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. to Provide Clinical Trial Services for International Trials in Chronic Lymphocytic Leukemia
24. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 24
Roche Partnership Expanding Market Presence Internationally
“By expanding our relationship, we are strengthening our ability to provide patients the best service possible.” Alvaro Soto, Roche Servicios, Central America & Caribbean General Manager
Highlights
CGI provides genomic and biomarker testing services to 14 countries in Central America and the Caribbean.
CGI won a global RFP to help a strategic personalized medicine initiative for Roche Servicios (Latin America)
Roche sends all patient samples to the Rutherford facility where they are catalogued and processed
CGI interacts with both Roche and the hospital staff (pathologists, oncologists and nurses) and supports delivery of reports through an online HIPAA compliant portal
CGI and Roche expanded this relationship in 2013 and will begin developing workshops and training programs to drive adoption of biomarker-based cancer diagnostics throughout Central America and the Caribbean
CGI and Roche recently further expanded this relationship with an exclusive multi-year deal in which CGI will develop a center of excellence for lung cancer testing utilizing Roche’s FDA-Approved cobas® platform
CGIX Press Release: Cancer Genetics, Inc. selected by Roche Servicios S.A. to provide services for the diagnosis and personalization of oncology treatment CGIX Press Release: Cancer Genetics, Inc. expands relationship with Roche Servicios S.A.
25. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 25
AstraZeneca Partnership A Testament to the Growing Global Awareness of the Value of the CGI Brand
“We chose to partner with Cancer Genetics in this endeavor because of their experience in biomarker-based diagnostic testing and their commitment to delivering timely and accurate results to healthcare professionals and patients.” Rodrigo Fernandez, Country President of AstraZeneca CAMCAR, S.A.
Highlights
CGI will provide biomarker and molecular based testing services focused on select oncology categories and trials
Services include complex testing for diagnosis and prognosis of cancer patients in Central America and the Caribbean
CGI will work in close conjunction with AstraZeneca on exploring expansion opportunities into additional geographic territories, further oncology categories, and into select oncology trials
The partnership will concentrate on multiple cancer categories, with lung cancer being an initial area of focus
CGIX Press Release: Cancer Genetics, Inc. Announces Partnership with AstraZeneca to Provide Biomarker & Molecular Based Testing
26. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 26
Collaborations with Premier Cancer Research Institutions Leading Differentiated Research & Driving Product Adoption
Research Collaboration/ Licensing
Clinical
Services
Partnership
Highlights
Kidney Cancer, DLBCL, MCL & FL
Joint Venture Focused on Oncology & Next Generation Sequencing
Cervical Cancer
DLBCL
CLL
Cervical Cancer & DLBCL
Cervical Cancer
Kidney Cancer
DLBCL, Head & Neck Cancers
CLL
27. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 27
Mayo Clinic Joint Venture Investing in the Future – OncoSpire Genomics
The Value and Focus of Next Generation Sequencing is Moving from Platforms to Clinically Relevant, Disease-Specific Applications
Highlights
JV, based in Rochester, MN, will develop clinical diagnostic products and services on NGS platform(s) in areas of high clinical need
Three initial projects in key oncology categories selected by the SRC (Scientific Review Committee): Lung Cancer, Multiple Myeloma, Follicular Lymphoma
CGI commits up to $6 M over initial three year period (2013 to 2015-16 expected)
Mayo commits to “in-kind” services and support, use of facilities, NGS capabilities and access to biorepository
Joint Venture is exclusive in the project areas selected by CGI & Mayo
Important company update and analyst day held November 22, 2013
Next Generation Sequencing in Oncology
28. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 28
OncoSpire Genomics Projects are Unique and Have High Value
1.6 million
new cases
200,000
new cases
20,920
new cases
Informed
Discovery
Clinical Development
Commercial Development
Market Entry
(with partners)
Lung Cancer
Multiple Myeloma
Follicular Lymphoma
Selected Projects Have Significant Clinical Value & May Yield Multiple Focused Panels to Become the Standard of Care in NGS-Based Oncology Management
29. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 29
Strong History of Growth CGI Revenue & Clinical Volume Trends (2009 – 2013)
54% Full Year 2013 Revenue Growth
$1.67
$2.52
$3.02
$4.30
$6.61
2009
2010
2011
2012
2013
2,321
3,146
3,622
6,610
10,771
2009
2010
2011
2012
2013
Total Revenue ($Mn)
Clinical Volume (Tests Processed)
31. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 31
Summary Statement of Operations (1st Half Comparison 2012-2014)
Income Statement Item
1H, 2012
1H, 2013
1H, 2014
Combined 1H, 2014*
Revenue
$1,983
$3,050
$2,942
$6,508
Gross Profit
74
701
149
1,781
Gross Margin (%)
3.7%
23.0%
5.1%
27.4%
Research & Development (R&D)
1,050
951
1,703
2,043
Sales & Marketing (S&M)
716
832
1,667
1,703
General & Administrative (G&A)
2,329
2,961
5,127
7,092
Operating Profit (Loss)
(4,021)
(4,043)
(8,348)
(9,056)
Net Income (Loss)
(2,933)
(6,782)
(6,673)
(7,417)
$ in thousands
* The “Combined 1H, 2014” results are the aggregation of first half 2014 of both Cancer Genetics, Inc. and Gentris Corporation. The amounts may not be indicative of future results.
Actual 06/30/14
All Cash*
$43,418
Stockholders’ Equity
40,463
$ in thousands * All cash included $6,000 restricted to collateralize a credit line
Balance Sheet Information
32. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 32
Consistent Focus on Gross Profit Improvements Additional Efforts Focused Operationally in US & India
Gross Profit Margin
Highlights of Initiatives
(52%)
(39%)
(3%)
9%
26%
(1,000)
(800)
(600)
(400)
(200)
0
200
400
600
800
2009
2010
2011
2012
2013
$ in Thousands
Decrease CGI Costs for Development & Services
Migrate DNA manufacture and NT Kits for CGI probes
Develop remove G-Band analysis capability
Develop remote FHACT® analysis capabilities
Move entire probe manufacturing & assembly
33. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 33
Multiple Customer Types Provide Diversified Revenue Mix With Covered Lives Already in Place
Selected Payors
Direct Bill Customer Types
Biotechs
Pharmas
Academic
Cancer Facilities
Community &
Regional Labs
72+ million covered lives through multiple payors:
18%
21%
58%
3%
Medicare
3rd Party Insurance
Companies,
Hospitals
& Care
Facilities
Payor Revenue Mix 1H, 2014
Reimbursement Based
Direct Bill / Pay Based
3rd Party Insurance
Medicare
1H, 2014
Probes
Companies, Hospitals
& Care Facilities
34. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 34
Experienced and Focused Management and Boards
Scientific Advisory Board
Andrea Califano, Ph.D.
Chairman of the Columbia Initiative for Systems Biology
Associate Director for Bioinformatics, Herbert Irving Comprehensive Cancer Ctr
Timothy A. Chan, M.D., Ph.D.
Principal Investigator, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center
Riccardo Dalla-Favera, M.D.
Director, Institute for Cancer Genetics at Columbia University
Vundavalli V. Murty, Ph.D.
Director, Cancer Cytogenetic Laboratory and Molecular Pathology at Columbia University
Hans-Guido Wendel, M.D.
Principal Investigator, Cancer Genetics Laboratory at Memorial Sloan-Kettering Cancer Center
Howard McLeod, PharmD
Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
Andrew D. Zelenetz, M.D., Ph.D.
Chief of Lymphoma Service and Head of Molecular Hemo-Oncology Laboratory, Department of Medicine at MSKCC
Raju Chaganti, Ph.D., FACMG Founder
•35+ years in cancer research; 38 at MSKCC
•Major discoveries in cancer genomics
•Published 350+ articles, 4 patents
Panna Sharma President & CEO
•15+ years as advisor to global life science & healthcare cos.
•Founded TSG Partners
•Chief Strategy Officer, iXL (IIXL)
Edward J. Sitar Chief Financial Officer & Treasurer
•30+ yrs in finance & deal making in the healthcare industry
•Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation (Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers & Lybrand
Jane Houldsworth, Ph.D. Vice President of R&D
•25+ years in translational oncology research
•Published 50+ articles, 4 patents
•NIH grantee
Chairman of the Board,
|
Keith Brownlie, CPA
|
Edmund Cannon
|
Raju Chaganti, Ph.D.
John Pappajohn
|
Franklyn Prendergast, M.D., Ph.D.
|
Paul Rothman, M.D.
|
Panna Sharma
Board of Directors
Officers & Management Team
35. 2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 35
Consistent Achievement of Milestones Expected in Coming Quarters
Increasing covered lives market access through additional payers & health care organizations
Launching multi-marker NGS panel for lymphoid malignancies
Additional international agreements with life science tools companies for DNA Probes and product distribution in key geographies
MatBA® – Next phase of data and results from Dana Farber and HUMC studies to help support value and reimbursement
Pursuing CE approval for IVDD use of FHACT® in E.U.
Additional news on biopharma partners & relationships
Pursuing additional indications for UroGenRA®-Kidney microarray
Close of BioServe transaction (Q3, 2014)
Migrated DNA-FISH Probe Manufacturing to India reducing cost, increasing capacity and improving operational flexibility
Launched UroGenRA®-Kidney, a unique microarray for kidney cancer diagnosis in collaboration with MSKCC
Collaborative Study of UroGenRA®-Kidney with Cleveland Clinic demonstrated 93% diagnostic accuracy – announced results at the AACR 105th Annual Meeting
Launched FHACT® outside the U.S. in collaboration with the National Cancer Institute research publication and in the U.S. as an LDT under CLIA
Promoted FHACT® at the ACOG Annual Meeting
Received CLIA Approval for MatBA®-MCL (Mantle Cell Lymphoma)
Finalized Agreement with Multiplan and Three Rivers which gave us access to 72+ million covered lives
Launched OncoSpire Genomics – A Next Generation Sequencing Joint Venture with Mayo Clinic and announced initial set of projects (lung cancer, multiple myeloma & follicular lymphoma)
Launched CALR Mutation Test – for the diagnosis of myeloproliferative neoplasms potentially evolving into acute leukemia
Announced Multi-Year PathAdvantage Collaboration – for FHACT® (cervical cancer)
Partnered with AstraZeneca – CGI will provide biomarker-based Dx in Central America and the Caribbean
Acquisition of Gentris Corporation – closed on July 16, 2014
Recent
Accomplishments
Upcoming Milestones and Value Drivers
36. For further information, please contact us at ir@cgix.com
Cancer Genetics, Inc.
Meadows Office Complex
201 Route 17 North
Rutherford, NJ 07070
(201) 528-9200
www.cancergenetics.com
100214